RxDoctor Payments Data

Naveen Anand, MD

Gastroenterology · Atlanta, GANPI 1841474541

Payments from drug & device makers

$5,727in general payments, 2019–2025

Across 70 payments — averaging $81.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Olympus Corporation Of The Americas$2K
  • Boston Scientific$1K
  • Ovesco Endoscopy USA, Inc.$647
  • Cook Medical LLC$489
  • Medtronic$484
  • Omega Medical Imaging, LLC$297
  • plus $717 from 7 others

What the payments were for

  • Travel & lodging$2,29440%
  • Food & beverage$3,43360%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Olympus Corporation Of The Americas18$1,804
Boston Scientific27$1,290
Ovesco Endoscopy USA, Inc.1$647
Cook Medical LLC7$489
Medtronic4$484
Omega Medical Imaging, LLC1$297
Olympus America Inc.3$179
Creo Medical Inc.2$178
AstraZeneca1$131
Micro-tech Endoscopy USA, Inc.1$102
AbbVie3$78
Takeda Pharmaceuticals U.S.A., Inc.1$33
Johnson & Johnson1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,727 in reported general payments places this provider in the 60th percentile of 492 gastroenterology providers in Georgia.

See all gastroenterology providers in Georgia

Medicare billing

Part B allowed, 2024
$61,759
Medicare patients
211
Services billed
462

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase24$102,397
LinzessLinaclotide13$18,729
Lubiprostone14$3,017
Pantoprazole Sodium155$2,827
Colestipol Hcl12$2,418
Omeprazole22$207
Furosemide11$37
Levofloxacin11$22

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$78$121,12637 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 492 gastroenterology providers in Georgia.

Other gastroenterology in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →